-- PATENT APPLICATION
-- Attorney Docket No. 25,835-11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	M. L. Collins, et al.
Serial No.:	08/238,080
Filing Date:	May 3, 1994
Title:	TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS
Art Unit:	1807
Examiner:	Dianne Rees, Ph.D.

CERTIFICATE OF MAILING & FACSIMILE RESPONSE

I hereby certify that this correspondence is being sent via facsimile to: Dianne Rees, at facsimile number (703) 305-3014, and is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date shown below.

LESLIE B. HENSON
(Printed Name)

Leslie B. Henson
(Signature)

July 9, 1997
(Date of Deposit)

TRANSMITTAL OF DECLARATION OF DAVID H. PERSING, M.D., PH.D.

The Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants submit herewith the Declaration of Dr. David H. Persing pursuant to 37 CFR §1.132 for purposes of traversing the Examiner's rejections of pending claims 25-50. Applicants submit that Dr. Persing's Declaration provides additional compelling evidence of the patentability of Applicants' claimed inventions.

In particular, Applicants have previously contended that practitioners in the nucleic acid hybridization and amplification arts at the time the invention was made were deterred from using nucleic acid hybridization to separate target from sample prior to amplification because of their concern over the loss of target prior to amplification resulting from the incomplete binding efficiency between hybridization probe and target. While the Examiner has acknowledged the legitimacy of Applicants' contention, the Examiner remains unpersuaded as to the patentability of Applicants' claimed inventions. The Examiner contends that Applicants'

submission is balanced by the consideration that practitioners would have been motivated to use hybridization to separate target from sample prior to amplification because doing so would provide a more specific target for amplification. (See the Examiner's Interview Summary for the Interview dated April 7, 1997) Applicants submit Dr. Persing's Declaration to overcome the Examiner's contention. Applicants submit Dr. Persing is an expert in the field of nucleic acid hybridization assays utilizing amplification methods such as PCR. Dr. Persing has been a practitioner in this field since about 1985 or before the invention was made. He is knowledgeable as to the practices and concerns of practitioners at that time. Dr. Persing's Declaration is also submitted to demonstrate that Applicants' invention provides advantages unanticipated by the art at the time the invention was made. His testimony is supported by published technical references.

Applicants submit Dr. Persing's testimony overcomes the Examiner's contentions that those skilled in the art would have been motivated to choose from the various available techniques and arrive at Applicants' intention. As Dr. Persing states, those practicing in this art at the time the invention was made were, in fact, concerned with the incomplete binding efficiencies of probe to target and the expected resulting loss of target, and were deterred from performing hybridization and separation prior to amplification as a result. (Dr. Persing's testimony is supported by the reference text **Diagnostic Molecular Microbiology** PRINCIPALS AND APPLICATIONS, attached as Exhibit 3 to his Declaration.) As Dr. Persing also states, this deterrence was reinforced by the general teachings of PCR practitioners that PCR was highly specific and could be made to selectively amplify a desired target in an otherwise complex sample so that the there was no need to risk losing target by hybridization and separation prior to amplification. Contrary to the Examiner's contentions, those practicing in this art were motivated against finding Applicants' invention rather than toward Applicants' invention.

Finally, Dr. Persing's Declaration demonstrates that Applicants' invention provides an additional advantage that was not perceived at the time the invention was made. This is the removal of amplification inhibitors from the amplification medium prior to the actual amplification of the target nucleic acids, which is also discussed in the recently submitted Mangiapan article. (See Transmittal of Art References filed April 17, 1997) Thus, in addition to enabling more specific

target amplification, Applicants' invention enables the amplification to proceed more efficiently than would have been expected at the time the invention was made.

Applicants submit that the Examiner has, with the benefit of hindsight, oversimplified the difficulties perceived by those skilled in this art at the time the invention was made. (The Examiner has suggested, for example, that the general teachings of the art at the time of the invention and thereafter were of the "quick and dirty" variety. (See the Examiner's Interview Summary for the Interview dated March 26, 1997)) To the contrary, however, and as demonstrated by Dr. Persing's Declaration, the practitioners in this field perceived real and substantial deterrents against Applicants' invention at the time it was made. Applicants submit the invention represents a significant advance for those interested in the selective amplification of specific nucleic acid targets.

Since a Notice of Appeal has been filed, Applicants suppose that submission of the Persing Declaration must be accompanied by a showing of good and sufficient reasons why it was not presented earlier. (See 37 CFR §1.195) Applicants submit the Persing Declaration includes statements that could not have been presented earlier. Applicants were not aware of the teachings from **Diagnostic Molecular Microbiology** and the Mangiapan article, which are cited and discussed in the Declaration until only recently. Thus, Applicants were not able to present Dr. Persing's Declaration earlier.

Applicants submit herewith an unsigned Declaration of Dr. Persing. Dr. Persing's signature will be obtained shortly and the executed Declaration will be submitted at that time. Applicants again wish to express their gratitude to the Examiner for the consideration extended by the Examiner to Applicants' representative.

Applicants submit that all claims are in condition for allowance, which action is earnestly solicited.

Respectfully submitted,
AMOCO CORPORATION

By: Norval B. Galloway

Norval B. Galloway
Attorney for Applicant
Registration No. 33,595

Date: 7/9/97

AMOCO CORPORATION
Law Department
3100 Woodcreek Drive
Downers Grove, Illinois 60515-5400
Phone: (630) 271-7417
Facsimile: (630) 271-7054

A:\Z2583511.PRS

-- PATENT APPLICATION --
-- Attorney Docket No. 25,835.11 --

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. L. Collins, et al.

Serial No.: 08/238,080

Filing Date: May 3, 1994

Title: TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS

Art Unit: 1807

Examiner: Dianne Rees, Ph.D.

DRAFT

DECLARATION OF DAVID H. PERSING, M.D., PH.D.

I, David H. Persing, M.D., Ph.D., declare and state as follows:

1. I am director of the Molecular Microbiology Lab of the Mayo Clinic, Rochester Minnesota. I have been employed by the Mayo Clinic since 1990. My work has been directed to the study of infectious diseases and includes the study of the application of nucleic acid hybridization assays in medical diagnostics.

2. I am a member of the Scientific Advisory Board of Vysis, Inc. I understand Vysis is a wholly owned company of Amoco Corporation, the owner of the subject patent application.

3. A copy of my curriculum vitae is attached as Exhibit 1. Briefly, I have been involved in molecular micriobiology research since about 1978. Our laboratory is currently one of the premier centers for the diagnosis of infectious diseases by molecular methods. Our lab has pioneered techniques for pathogen discovery and contamination control, and has discovered several new pathogens as a result.

4. A list of my scientific publications is attached as Exhibit 2.

5. I have been provided with and have reviewed copies of the following documents:

(a) Patent Application U.S. Serial No. 08/238,080 entitled Target And Background Capture Methods With Amplification For Affinity Assays naming Collins et al. as inventors;

(b) A document entitled Preliminary Amendment And Response To Restriction Requirement dated December 5, 1995;

(c) U.S. Patent No. 4,851,331 entitled Method And Kit For Polynucleotide Assay Including Primer-Dependant DNA Polymerase naming Vary et al. (the "Vary patent") as inventors;

(d) European Patent Publication No. 0 139 489 entitled Sandwich Hybridization Method For Nucleic Acid Detection naming Hansen (the "Hansen" application) as the inventor;

(e) European Patent Publication No. 0 159 719 entitled Hybridization Method For the Detection Of Genetic Materials naming Rabbani et al. (the "Rabbani" application) as inventors;

(f) A transmittal letter from the Patent Office and accompanying Office Action Summary dated June 20, 1996;

(g) A transmittal letter from the Patent Office and accompanying Office Action Summary dated January 17, 1997; and

(h) The article "Sequence Capture-PCR Improves Detection of Mycobacterial DNA in Clinical Specimens," by Mangiapan et al., J. Clin. Microbiol., 34(5): 1209-1215 (1996).

6. I have reviewed claims 25 and 31 as presented in the Preliminary Amendment. I am informed that the inventions claimed in these claims were made on or before December 21, 1987.

7. I have been familiar with and been a practitioner of nucleic acid hybridization assays and various amplification techniques used with nucleic acid hybridization assays since about 1985. I have generally followed the literature of assay methods using nucleic acid hybridization since about 1985. As indicated in Exhibit 2, I have published a number of publications relating to these techniques and am a Editor-in-Chief of the reference text **Diagnostic Molecular Microbiology** PRINCIPALS AND APPLICATIONS.

8. I have been asked to consider whether the methods recited in claims 25 and 31 would have been obvious to those practicing in the field of nucleic acid hybridization assays and utilizing techniques for amplifying nucleic acids such as the polymerase chain reaction or PCR in light of the Vary patent, the Hansen application and the Rabbani application. In my opinion, the methods recited in claims 25 and 31 would not have been obvious to such practicioners in light of these references.

9. The Vary patent discloses a method for assaying for polynucleotides using primer dependent DNA polymerase. More particularly, the patent discloses

> a method for the determination of a target nucleotide sequence in the nucleic acid of a biological [sample] which comprises the steps:
> (a) contacting the sample with a probe polynucleotide of a sufficient length under conditions sufficient for the probe polynucleotide to bind to the target nucleotide sequence and form a hybrid having a double-stranded portion including the 3' end of the probe polynucleotide, with the sample nucleic acid strand extending in a 3' to 5' direction beyond the 3' end of the probe polynucleotide;
> (b) extending the probe polynucleotide strand of the hybrid beyond its 3' end in the 5' to 3' direction on the sample nucleic acid strand by incorporating nucleoside triphosphates from solution, a plurality of the nucleotides incorporated into the extended probe strand being detectably-modified nucleotides; and
> (c) detecting detectably-modified nucleotides which have been incorporated into probe polynucleotide strand as a measure of target nucleotide sequence in the biological sample. (Col. 1, line 54 - col. 2, line 6)

The primary feature of the invention is the selective incorporation of detectably labeled nucleotides into an elongation segment formed on a sample polynucleotide containing a target nucleotide sequence as a template and as an extension of a probe polynucleotide (which need not be labeled, but may contain a site for specific immobilization) as primer. (Col. 1, lines 47 - 53) More generally, the patent discloses a method for detecting a target polynucleotide in a sample comprising hybridizing a primer to the target polynucleotide, extending the primer, immobilizing the double-stranded polynucleotide product of the primer extension on a support, separating the double-stranded polynucleotide on the support from the sample and detecting the amplified polynucleotides. The double-stranded polynucleotide is then immobilized on a solid support and detected. Preferably, the double-stranded polynucleotide is separated from the sample for detection. (Col. 4, line 6 et seq.)

The patent does not disclose or suggest immobilizing and separating the target polynucleotide from the sample prior to hybridization of the primer to the target or primer extension.

Moreover, it is not even clear that the patent discloses amplification as that term is generally understood in the art and as is intended by claims 25 and 31. Target amplification generally means increasing the number of target polynucleotides manifold, typically exponentially. For example, amplification of nucleic acids by the polymerase chain reaction (PCR) follows primer extension with separation of the double-stranded primer extension product into single-stranded polynucleotides and repeating the process steps (hybridization of primer to target polynucleotide, primer extension and separation of the double-stranded product into more single-stranded polynucleotides) thereby increasing the population of detectable target polynucleotides exponentially. The Vary patent discloses only a single primer extension and detection of the extension product. Thus, in absolute terms. the number of polynucleotides actually detected by Vary's method can be no more than the number of target polynucleotides initially present in the sample. In contrast, the number of polynucleotides detected following target amplification can easily be more than a million times greater than the number of polynucleotides initially present in the sample.

10. The Hansen application discloses a method for detecting specific nucleic acids by providing the nucleic acid to be detected in single-stranded form and thereafter contacting it with a labeled nucleic acid probe specific for a given section of the nucleic acid strand. Additionally, a biotinylated nucleic acid probe specific for a different portion of the nucleic acid strand, is bonded to an avidin coated microparticle. The strand having the labeled probe hybridized to it is then mixed with the avidin coated microparticles. The probes are allowed to bind to the target nucleic acid so that the target becomes bound to the microparticle. The microparticles are then separated from the sample. The coupling of biotin to avidin is sufficiently strong that the targets remain bound to the microparticles and so are separated from the sample with the microparticles. The bound material is then assayed for the presence of the label signalling the presence of the target polynucleotide. (Page 2, lines 14 -33) The application discloses that the order of reaction among the assay components may be varied to suit the needs of the investigator. (Page 6, lines 17-21) The primary feature of the application appears to be the use of the strong binding characteristics of biotin and avidin in facilitating the separation of the target from the sample prior to detection. The application does not disclose or even consider target amplification as a part of its methods.

11. The Rabbani application discloses methods for the detection of target genetic material having a desired base sequence or gene, mutations and the deletion of a gene or base. The methods are based upon techniques which utilize two labeled single-stranded polynucleotide segments which are complementary to the same or opposite strands of the target material. These methods result in the formation of double or multi-hybrids. The multi-hybrids are detected by means of various labels. The application does not disclose or even consider target amplification as a part of its methods.

12. I have reviewed the arguments made by the Examiner in concluding that claims 25 and 31 as presented in the Preliminary Amendment are obvious in view of the Vary patent and the Hansen and Rabbani applications. I disagree with the Examiner's conclusion for the following reasons. As noted above, none of these references discloses any real teachings regarding the use of amplification in a nucleic acid hybridization assay. Accordingly, I believe it is inappropriate for the Examiner to apply the disclosure of these references to the use of amplification techniques for enhancing assay sensitivity. Although it may appear obvious today to apply these references as the Examiner has done, I believe that to do so overlooks or greatly oversimplifies the problems actually encountered by practitioners attempting to obtain highly sensitive assays using target amplification. I do not believe the methods of claims 25 and 31 were obvious in light of these references in December 1987.

It is necessary to keep in mind that the inclusion of target amplification to nucleic acid hybridization assays adds an additional, significant level of complexity to assay methodology. Additional materials are required; additional process steps are required; additional time is required; and additional cost is required to add amplification to conventional (unamplified) assay methodology. Those working with nucleic acid hybridization assays had no real incentive to add to their methods the complexity attendant to amplification unless the object targets were expected to be present in levels below the detection level of their conventional methods.

As techniques such as PCR were developed for amplifying nucleic acids, those practicing hybridization assays sought to incorporate the new amplification techniques into their methods. Initially, users and proponents of PCR believed that PCR was highly specific and could be made to selectively amplify the desired target in an otherwise complex sample system. Practitioners believed that adequate specificity could be imparted to the amplification by careful selection of the primers used in the amplification so that additional steps for isolating target prior to amplification were not required. Since the addition of such isolation steps would be costly and time consuming, would further complicate the assay and was generally believed to be unnecessary; those who were adding amplification to their nucleic acid hybridization assays had a strong incentive to avoid the addition of target

isolation steps to their hybridization assays. It was not until much later that it became apparent that non-specific amplification was occurring despite the careful selection of primers, i.e., that even careful selection of primers would not permit the selective amplification of a particular nucleic acid. I believe this realization did not occur until after December 1987.

13. I believe there is another reason why practicioners of hybridization assays were reluctant to use hybridization techniques to purify their intended targets from the initial sample system prior to amplification. This is the lack of complete binding efficiency in the initial target capture step. It is and was generally well understood that the binding efficiency of (capture) probe to target is substantially less than 100%. Thus, in sample systems where the presence of target nucleic acid is already known to be low, the lack of high binding efficiency meant that significantly less than the already low number of targets present in the sample would be captured and survive separation from the sample for amplification, thereby decreasing the already low amount of target available for detection. This concern over the low binding efficiencies of the capture step has persisted as is evidenced at page 127 in the section addressing Target Capture techniques from Chapter 6 of the reference text **Diagnostic Molecular Microbiology** (copyright 1993), attached as Exhibit 3. ("However, to date there are no published studies that demonstrate efficient capture and detection of fewer than 100 target molecules, ...")

Accordingly, I do not agree with the Examiner's conclusion that those incorporating amplification techniques into nucleic acid hybridization assays in or before December 1987 would have concluded that the methods claimed in claims 25 and 31 of the Preliminary amendment were obvious in light of the Vary patent, the Hansen application and the Rabbani application. To the contrary, coupled with the conventional understanding at that time (that careful selection of primers would permit adequate selectivity of the target and specificity in the amplification product), the practitioners' concern regarding imperfect binding efficiencies and the expected loss of real target before amplification occurred reinforced their incentive to avoid further complicating their assays by the addition of target separation steps to their assays.

I do not believe that the concerns of practitioners regarding imperfect binding efficiencies would have been overcome by the disclosure of the Hansen application which addressed a much more simplified assay system. There is nothing in Hanson application, for example, to suggest that practitioners should elect to first separate less than all of the scarce target from the sample before completing the assay.

14. Finally, I would also mention that the methods of Claims 25 and 31 have provided an additional advantage which was unexpected in or before December 1987. This is the elimination of amplification inhibitors normally present in the sample system. For example, as indicated by the article by Mangiapan, many clinical samples contain PCR inhibitors such as hemoglobin and sodium dodecyl sulfate. By separating the target from the sample prior to amplification, Applicants' methods effectively remove these inhibitors from the system enabling amplification to proceed optimally. This has an obvious beneficial effect on the overall assay.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledged that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of the Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.

Date: David H. Persing, M.D., Ph.D.

EXHIBIT 1:

CURRICULUM VITAE

DAVID H. PERSING, M.D., PH.D.

CURRICULUM VITAE

DAVID H. PERSING, M.D., PH.D.

David Harold Persing, M.D., Ph.D.

Date of Birth: June 13, 1955, San Jose, California

Address: 2225 48th Street, S.W., Rochester, MN 55902

Telephone: (507) 284-2876 (Work)
(507) 280-7696 (Home)
E-mail: persing@mayo.edu

Marital Staus: Married

Education:

September 1974 - June 1979
California State University, San Jose, California
B.A. in Biochemistry awarded June 1979

October 1980 - May 1988
School of Medicine, University of California, San Francisco

October 1981 - May 1988
Medical Scientist Training Program,
University of California, San Francisco

September 1982 - March 1987
Graduate Program in Biochemistry and Biophysics,
Division of Genetics, University of California,
San Francisco

March 1988
Ph.D. granted, Department of Biochemistry and
Biophysics, University of California, San Francisco

May 1988
M.D. granted, School of Medicine, University of California, San Francisco

July 1988 - June 1990
Resident and Fellow, Department of Laboratory Medicine, Yale School of Medicine

July 1989 - September 1990
Research Fellow, Department of Cell Biology, Yale School of Medicine

Honors:

Graduation with highest honors,
California State University, San Jose, California, 1979

Departmental Honors in Chemistry, 1979

Finalist, Dean's Prize for Research, School of Medicine, 1981

Graduate Dean's prize for Student Research,
University of California, San Francisco, 1984

Gip A. Hudson Award for the study of liver diseases,
National Student Research Forum, Galveston, Texas, 1985

James McLaughlin Award for the study of infectious diseases,
National Student Research Forum, Galveston, Texas, 1985

University Patent Funds Award, 1986

Young Investigator Award,
Academy of Clinical Laboratory Physicians and Scientists, 1989

Mayo Foundation Scholar, 1990

U. S. Patent Application: "Sensitive and Specific Detection of B. burgdorferi by Nucleic Acid Amplification," 1994

U. S. Patent Application: "Specific Detection of Rifampin Resistant Mycobacterium tuberculosis by Nucleic Acid Amplification," 1994

U.S. Patent Application: "Method for Detecting Borrelia burgdorferi Infection," 1996

College of American Pathologists, Microbiology Resource Committee, 1993-present

ASM Foundation Lectureship, 1995-1997

Associate Editor: Journal of Clinical Microbiology, 1996-

Associate Editor: Molecular Diagnosis, 1996-

1997 Justus Strom Award , Swedish Medical Society

Dubious Honors:

Consultant to Criminal Attorney Barry Scheck and invited expert witness, O.J. Simpson criminal trial

Editorial Boards:

Journal of Clinical Microbiology (1990-1996)
Diagnostic Microbiology and Infectious Diseases (1994-96)
New England Journal of Medicine (Regular Reviewer)
Gastroenterology (Regular Reviewer)
Journal of Infectious Diseases (Guest Reviewer)

Scientific Advisory Boards:

Vysis, Inc., Naperville, IL (1995-present)
Corixa, Inc., Seattle, WA (1995-present)
BioMerieux, Marcy L'Etoile, France (1996-present)

Licensure and Certification:

Status: Medicine and Surgery License #35080, State of Minnesota
Board Certified Forensic Examiner
Board Eligible, Clinical Pathology

Appointments:

Summer Research Fellowship, University of California,
San Francisco, School of Medicine, 1980

September 1981 to May 1988:
Medical Scientist Training Program, University of California, San Francisco

July 1988 to June 1990:
Resident, Department of Laboratory Medicine, Yale University School of Medicine

July 1990 to September 1990:
Mayo Foundation Scholar, Department of Cell Biology, Yale University School of Medicine

September 1990 to June 1994:
Senior Associate Consultant, Divisions of Clinical Microbiology, Experimental Pathology and Infectious Diseases, Mayo Clinic/Foundation

June 1994 to present:
Consultant, Divisions of Clinical Microbiology, Experimental Pathology and Infectious Diseases, Mayo Clinic/Foundation

January 1991 to June 1995:
Assistant Professor, Department of Laboratory Medicine and Pathology, Mayo Medical School

July 1995 to present:
Associate Professor of Microbiology, Mayo Medical School, Mayo Clinic/Foundation

July 1995 to present:
Associate Professor, Department of Laboratory Medicine and Pathology, Mayo Medical School

September 1991 to present:
Adjunct Assistant Professor, Department of Biology/
Microbiology, University of Wisconsin-La Crosse

1996 to present:
M.D.- Ph.D. Program Council, Mayo Medical School

Societies:

American Association for the Advancement of Science
California Medical Association
American Society for Microbiology
Minnesota Medical Association
American Medical Association
American Society for Tropical Medicine and Hygiene
American College of Rheumatology

Teaching Experience:

Teaching Assistant, Chemistry for Engineers, San Jose State University, September 1979 to June 1980

Graduate Teaching Assistant, Introductory Biochemistry
UC San Francisco, September 1982 to April 1983

Instructor, Biochemistry National Boards Review Course,
School of Dentistry, UC San Francisco, 1983-1986

Biochemistry Advisor, Health Science Special Services
Summer Program, 1984-1986

Laboratory Instructor, Medical Microbiology Course, Yale School of Medicine, 1988-1989

Lecturer, Medical Microbiology Course, Yale School of Medicine, 1989

Medical Microbiology Course, Mayo Medical School, 1991-present

Volunteer Services:

Department of Public Health, Huehuetenango, Guatemala,
1977-1978

National Ski Patrol, Alpine Meadows and Homewood, CA, 1978-1981

Dorothy Day House, Rochester, MN, 1992-present

Extracurricular Activities:

Skiing, vintage automobile restoration, brass ensemble (trombone)

Research Experience and Supervisors:

Spring 1979 - Summer 1980
Dr. Robert Fowler, Department of Biology, San Jose State University. Mutational specificity of the base analogue, 2-aminopurine in Escherichia coli.

Summer 1980 - Spring 1981
Dr. Phillip Coffino, Department of Microbiology, UC San Francisco. Mechanism of 2-aminopurine mutagenesis in mouse T-lymphosarcoma cells.

Summer 1981 - Fall 1981
Dr. Harold E. Varmus, Department of Microbiology, UC San Francisco. Molecular analysis of mutant src alleles.

Summer 1982 - Winter 1983
Dr. Patrick O'Farrell, Department of Biochemistry, UC San Francisco. Isolation and characterization of DNA clones representing the engrailed locus of Drosophila melanogaster.

Spring 1983 to 1988
Drs. Donald Ganem and Harold Varmus (1989 Nobel Laureate) (thesis co-advisors) Identification and characterization of the presurface proteins of hepatitis B virus.

July 1989 to September 1990
Dr. Ari Helenius, Department of Cell Biology, Yale School of Medicine.
Papovaviruses: Assembly, Disassembly, and Cellular Interactions.

Current Research Interests:

Laboratory-based, extramurally funded programs

1) Immunological interactions of tick-borne infections
2) Determinants of microbial persistence and tissue tropism
3) Effects of T cell differentiation on disease expression
4) Identification of novel T cell adjuvants from microbial sources

Clinical research

1) Association of viral heterogeneity and host immunogenetic determinants in viral disease expression
2) Pathogen discovery by broad-range amplification techniques
3) Association of infections with cancer and chronic human diseases

Extramural Support:
NIH - Allergy and Infectious Diseases: 1-PO1-AI30548-01-A1 (9/1/91 - 8/31/96)

Lyme Disease: Pathogenesis and Protection (Yale Program Project Grant),
P.I.: S. W. Barthold, D.V.M., Ph.D. Co-investigator: David H. Persing, M.D., Ph.D.;
$295,407 award amount, direct costs

NIH - Allergy and Infectious Diseases: 1-R01-AI32403-01 (9/30/91 - 8/31/97)
Mechanisms of Biological Variation in Lyme Disease,
P.I.: D. H. Persing, M.D., Ph.D.; $1,006,775 award amount, direct costs, Status: renewal pending

NIH - Arthritis Institute 1-R01-AR41497-01 (9/1/91 - 8/31/95)
Molecular Diagnosis and Monitoring of Lyme Disease,
P.I.: D. H. Persing, M.D., Ph.D.; Co-funded with 1-RO1-AI32403-01;$227,359 award amount, direct costs; Status: decided against renewal of AR portion

Centers for Disease Control - U50/CCU510343- (4/15/94 - 2/1/98)
Genetic Diversity of B. burgdorferi in the United States;
P.I.: D. H. Persing, M.D., Ph.D.; $120,000 total costs per year

Centers for Disease Control - U50/CCU510528 (11/1/97 - 10/31/00)
Recombinant Immunoassays for Detection of Babesia microti Infection;
P.I.: David H. Persing, M.D., Ph.D.; $62,500 per year, direct costs

NIH - Allergy and Infectious Disease: 1-R01-AI45253-01 (9/30/94-9/29/99) Animal Models for Chronic Lyme Disease;
P.I.: Stephen W. Barthold, D.V.M., Ph.D.; Co-investigator: David H. Persing, M.D., Ph.D.; Co-investigator portion: $683,114 total award amount, direct costs

Chiron Corporation - Molecular Diagnostic Assay Development Award (12/1/92-present);
Co-investigator: David H. Persing, M.D., Ph.D.; Coinvestigator portion: $104,000 per year, direct costs

Corixa Corporation - 4-1-96 to present (indefinite termination) Identification of Microbial Biomolecules with Novel Immunologic Properties;
P.I.: David H. Persing, M.D., Ph.D.; $50,000 per year, direct costs

NIH - Allergy and Infectious Disease 1-R01-AI41103-0; Investigation of the Natural History of Babesiosis (5/1/97 - 5/31/00); $124,914 per year, direct costs

EXHIBIT 2:
PUBLICATIONS
DAVID H. PERSING, M.D., PH.D.

PUBLICATIONS

DAVID H. PERSING, M.D., PH.D.

Books:

Persing, D.H., T.F. Smith, T.J. White, and F. Tenover (eds). (1993) Diagnostic Molecular Microbiology: Principles and Applications, ASM Press, Washington, DC

Persing, D.H. (1996) PCR Protocols for Emerging Infectious Diseases, ASM Press, Washington, DC

Book Chapters & Reviews:

Persing, D.H., H.E. Varmus, and D. Ganem. (1985) Antibodies to preS and X determinants arise during natural infection with ground squirrel hepatitis virus. In The Molecular Biology of Hepatitis Viruses, Cold Spring Harbor Press.

Persing, D.H., H.E. Varmus, and D. Ganem. (1986) Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. In The Molecular Biology of Hepatitis Viruses, Cold Spring Harbor Press.

White, T.J., R. Madej, and D.H. Persing. (1992) The polymerase chain reaction: clinical applications. In Advances in Clinical Chemistry, Academic Press, San Diego, CA, pp. 161-196.

Persing, D.H. (1992) Nucleic acid amplification techniques in the diagnosis of infectious diseases. In Clinical Laboratory Medicine, R. C. Tilton, ed., Mosby Year Book, pp. 572-581.

Campbell, S., P. Fiedler, and D.H. Persing. (1992) Nucleic acid amplification techniques in clinical diagnostics. In Manual of Clinical Laboratory Immunology, American Society for Microbiology, Washington, DC.

Persing, D.H., S.W. Barthold, and S.E. Malawista. (1992) Molecular detection of Borrelia burgdorferi. In Lyme Disease: Molecular and Immunologic Approaches, Cold Spring Harbor Laboratory Press, pp. 299-315.

Barthold, S.W., M. de Souza, E. Fikrig, and D.H. Persing. (1992) Lyme borreliosis in the laboratory mouse. In Lyme Disease: Molecular and Immunologic Approaches, Cold Spring Harbor Laboratory Press, pp. 223-242.

Podzorski, R.P., and D.H. Persing. (1995) Molecular detection and identification of microorganisms. In Manual of Clinical Microbiology, 6th edition, Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds.), pp. 130-157, ASM Press, Washington, DC.

Relman, D.A., and D.H. Persing. (1996) Genotypic methods for microbial identification. In PCR Protocols for Emerging Infectious Diseases, ASM Press, Washington, DC, pp. 3-31.

Persing, D.H., D.A. Relman, and F.C. Tenover. (1996) Genotypic detection of antimicrobial resistance. In PCR Protocols for Emerging Infectious Diseases, ASM Press, Washington, DC, pp. 33-57.

Hofmeister, E.K., D.H. Persing, L. Mann, and G.L. Woods. (1996) Spirochete infections. In Clinical Diagnosis and Management by Laboratory Methods. Henry, J.B. (Ed.), 19th edition, W.B. Saunders, Philadelphia, PA.

Whelan, A.C.,and Persing, D.H. (1996) The role of nucleic acid amplification and detection in the clinical laboratory. Ann. Rev. Microbiol. 50:349-73.

Persing, D.H. (1997) Babesiosis. In Pathology of Infectious Diseases, Volume I & II. Connor, D.H., F.W. Chandler, H.J. Manz, D.A. Schwartz, and E.E. Lack (Eds.), Appleton & Lange, Stamford, CT.

Zheng, X., and D.H. Persing. Genetic amplification techniques for the diagnosis of infectious disease. In Rapid Methods. Specter, S. (Ed.)

Original Articles:

Persing, D.H., L. McGinty, C.W. Adams, and R.G. Fowler. (1981) Mutational specificity of the base analogue, 2-aminopurine, in E. coli. Mutation Research 83:25-37.

Caras, I.W., M.A. MacInnes, D.H. Persing, P. Coffino, and D.W. Martin. (1982) Mechanism of 2-aminopurine mutagenesis in mouse T-lymphosarcoma cells. Mol. Cell. Biol. 2:1096-1103.

Persing, D.H., H.E. Varmus, and D. Ganem. (1985) A frameshift mutation in the pre-S region of the human hepatitis B virus genome allows production of surface antigen particles but eliminates binding to polymerized albumin. Proc. Natl. Acad. Sci. USA 82:3440-3444.

Persing, D.H., H.E. Varmus, and D. Ganem. (1986) Antibodies to preS and X determinants arise during natural infection with ground squirrel hepatitis virus. J. Virol. 60: 177-184.

Persing, D.H., H.E. Varmus, and D. Ganem. (1986) Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. Science 234:1388-1391.

Persing, D.H., H.E. Varmus, and D. Ganem. (1987) The preS1 protein of hepatitis B virus is acylated at its N-terminus with myristic acid. J. Virol. 61:1672-1677.

Persing, D.H., and M.L. Landry. (1989) In vitro Amplification Techniques for the detection of Nucleic acids: New Tools for the Diagnostic Laboratory. Yale J. Biol. Med. 62:159-171.

Persing, D.H., S.R. Telford, A. Spielman, and S.W. Barthold. (1989) Detection of Borrelia burgdorferi infection in Ixodes dammini ticks using the polymerase chain reaction. J. Clin. Micro. 28:566-572.

Persing, D.H., S.R. Telford III, P.N. Rys, D.E. Dodge, T.J. White, S.E. Malawista, and A. Spielman. (1990) Detection of Borrelia burgdorferi DNA in museum specimens of Ixodes dammini ticks. Science 249:1420-1423.

Persing, D.H., S.R. Telford III, A. Spielman, and S.W. Barthold. (1990) Detection of Borrelia burgdorferi infection in Ixodes dammini ticks with the polymerase chain reaction. J. Clin. Microbiol. 28:566-572.

Barthold, S.W., D.H. Persing, A. Armstrong, and R.A. Peeples. (1991) Kinetics of Borrelia burgdorferi dissemination following intradermal inoculation of mice. Am. J. Path. 139:263-273.

Persing, D. H. (1991) Polymerase chain reaction: Trenches to benches. J. Clin. Micro. 29:1281-1285.

Malawista, S.E., R.T. Schoen, T.L. Moore, D.E. Dodge, T.J. White, and D.H. Persing. (1992) Failure of multitarget detection of B. burgdorferi-associated DNA sequences in synovial fluids of patients with juvenile rheumatoid arthritis: a cautionary note. Arthr. & Rheum. 35:246-247.

Persing, D.H., D. Mathiesen, W.F. Marshall, S.R. Telford III, A. Spielman, J.W. Thomford, and P.A. Conrad. (1992) Detection of Babesia microti by polymerase chain reaction. J. Clin. Microbiol. 30:2097-2103.

Armstrong, A.L., S.W. Barthold, D.H. Persing, and D.S. Beck. (1992) Carditis in Lyme disease susceptible and resistant strains of laboratory mice infected with Borrelia burgdorferi. Am. J. Trop. Med. Hyg. 47(2):249-258.

Conrad, P.A., J. Thomford, A. Marsh, S.R. Telford III, J. Anderson, A. Spielman, E. A. Sabin, I. Yamane, and D.H. Persing. (1992) Ribosomal DNA probe for differentiation of Babesia microti and B. gibsoni isolates. J. Clin. Microbiol. 30:1210-1215.

Gustaferro, C.A., and D.H. Persing. (1992) Chemi-luminescent universal probe for bacterial ribotyping. J. Clin. Microbiol. 30:1039-1041.

Fikrig, E., S.W. Barthold, D.H. Persing, X. Sen, F.S. Kantor, and R.A. Flavell. (1992) Borrelia burgdorferi strain 25015: characterization of OspA and vaccination against infection. J. Immunol. 148:2256-2260.

Persing, D.H., and J. Rakela. (1992) Polymerase chain reaction for detection of hepatitis viruses: Panacea or purgatory? Gastroenterology 103:1098-1099.

Shapiro, E.D., M.A. Gerber, N.B. Holabird, A.T. Berg, H.M. Feder, Jr., G.L. Bell, P.N. Rys, and D.H. Persing. (1992) A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N. Engl. J. Med. 327:1769-1773.

Persing, D.H. (1992) Diagnostic molecular microbiology: current challenges and future directions. Diagn. Microbiol. Infect. Dis. 16:159-163.

Meier, A., D.H. Persing, M. Finken, and E.C. Böttger. (1993) Elimination of contaminating DNA within PCR reagents-implications for a general approach to detect uncultured pathogens. J. Clin. Microbiol. 31:646-652.

Rys, P.N., and D.H. Persing. (1993) Preventing false positives: quantitative evaluation of three protocols for inactivation of polymerase chain reaction amplification products. J. Clin. Microbiol. 31:2356-2360.

Espy, M.J., T.F. Smith, and D.H. Persing. (1993) Dependence of polymerase chain reaction product inactivation protocols on amplicon length and sequence composition. J. Clin. Microbiol. 31:2361-2365.

Podzorski, R.P., and D.H. Persing. (1993) PCR: The next decade. Clin. Microbiol. Newslett. 15:137-144.

Quick, R.E., B.L. Herwaldt, J.W. Thomford, M.E. Garnett, M.L. Eberhard, M. Wilson, D.H. Spach, J.W. Dickerson, S.R. Telford III, K.R. Steingart, R. Pollock, D.H. Persing, J.M. Kobayashi, D.D. Juranek, and P.A. Conrad. (1993) Babesiosis in Washington State: a new species of Babesia. Ann. Intern. Med. 119:284-290.

Barthold, S.W., M.S. de Souza, J.L. Janotka, A.L. Smith, and D.H. Persing. (1993) Chronic Lyme borreliosis in the laboratory mouse. Am. J. Pathol. 143:959-972.

Laskus, T., J. Rakela, J.W. Mosley, M. Nowicki, and D.H. Persing. (1993) Prevalence and nucleotide sequence analysis of pre-core mutations among patients with fulminant hepatitis in the USA. Gastroenterology 105:1173-1178.

Nocton, J.J., F. Dressler, B.J. Rutledge, P.N. Rys, D.H. Persing, and A.C. Steere. (1994) Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid in Lyme arthritis. N. Engl. J. Med. 330:229-234.

Persing, D.H., B.J. Rutledge, P.N. Rys, D.S. Podzorski, K.D. Reed, P.D. Mitchell, B. Lin, and S.E. Malawista. (1994) Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. J. Infect. Dis. 169:664-668.

Yang, L., J.H. Weis, E. Eichwald, C.P. Kolbert, D.H. Persing, and J.J. Weis. (1994) Heritable susceptibility to Borrelia burgdorferi induced arthritis is dominant and is associated with persistence of high numbers of spirochetes in tissues. Infect. Immun. 62:492-500.

Thomford, J.W., P.A. Conrad, S.R. Telford, D. Mathiesen, B.H. Bowman, A. Spielman, M.J. Eberhard, B.L. Herwaldt, R.E. Quick, and D.H. Persing. (1994) Cultivation and phylogenetic characterization of a newly recognized human pathogenic protozoan. J. Infect. Dis. 169:1050-1056.

Laskus, T., J. Rakela, and D.H. Persing. (1994) The stem-loop structure of the cis-encapsidation signal is highly conserved in naturally occurring hepatitis B virus variants. Virology 200:809-812.

Laskus, T., J. Rakela, M.J. Tong, M. Nowicki, J.W. Mosley, and D.H. Persing. (1994) Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. J. Hepatol. 20:837-841.

Persing, D.H., D. Mathiesen, D. Podzorski, and S.W. Barthold. (1994) Genetic stability of Borrelia burgdorferi recovered from chronically infected laboratory mice. Infect. Immun. 62:3521-3527.

Dicaudo, D.J., W.P.D. Su, W.F. Marshall, S.E. Malawista, S.W. Barthold, and D.H. Persing. (1994) Acrodermatitis chronica atrophicans in the United States: clinical and histopathologic features of six cases. Cutis 54:81-84.

Geha, D.J., J.R. Uhl, C.A. Gustaferro, and D.H. Persing. (1994) Multiplex PCR for identification of methicillin-resistant staphylococci in the clinical laboratory. J. Clin. Microbiol. 32:1768-1772.

Marshall, W.F. III, S.R. Telford III, P.N. Rys, B.J. Rutledge, D. Mathiesen, A. Spielman, and D.H. Persing. (1994) Detection of Borrelia burgdorferi DNA in museum specimens of Peromyscus leucopus. J. Infect. Dis. 170:1027-1032.

Malawista, S.E., S.W. Barthold, and D.H. Persing. (1994) Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J. Infect. Dis. 170:1312-1316.

Laskus, T., J. Rakela, J.L. Steers, R.H. Wiesner, and D.H. Persing. (1994) Precore and contiguous regions of hepatitis B virus in liver transplantation for end-stage hepatitis B. Gastroenterology 107:1774-1780.

Hunt, J.M., G.D. Roberts, L. Stockman, T.A. Felmlee, and D.H. Persing. (1994) Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures and in clinical specimens. Diagn. Microbiol. Infect. Dis. 18:219-227.

Laskus, T., J. Rakela, M.J. Tong, and D. H. Persing. (1994) Nucleotide sequence analysis of the precore region in patients with spontaneous reactivation of chronic hepatitis B. Dig. Dis. Sci. 39:2000-2006.

Laskus, T., J. Rakela, R.H. Wiesner, J.L. Steers, and D.H. Persing. (1994) Lack of evidence for hepatitis B virus (HBV) infection in fulminant non-A, non-B hepatitis. Dig. Dis. Sci. 39:1677-1682.

Tenover, F.C., M.B. Huang, J.K. Rasheed, and D.H. Persing. (1994) Development of PCR assays to detect ampicillin resistance genes in cerebrospinal fluid samples containing Haemophilus influenzae. J. Clin. Microbiol. 32:2729-2937.

Laskus, T., J. Rakela, J.L. Steers, R.H. Wiesner, and D.H. Persing. (1994) Precore and contiguous regions of hepatitis B virus in liver transplantation for end-stage hepatitis B. Gastroenterology 107:1774-1780.

Reed, K.D., P.D. Mitchell, D.H. Persing, and C.P. Kolbert. (1995) Transmission of human granulocytic ehrlichiosis [letter]. J. Amer. Med. Assoc. 273:23.

Persing, D.H., B.L. Herwaldt, C. Glaser, R.S. Lane, J.W. Thomford, D. Mathiesen, P.J. Krause, D.F. Phillip, and P.A. Conrad. (1995) Infection with a Babesia-like organism in northern California. N. Engl. J. Med. 332:298-303.

Whelen, A.C., T.A. Felmlee, J.M. Hunt, D.L. Williams, G.D. Roberts, L. Stockman, and D.H. Persing. (1995) Direct genotypic detection of Mycobacterium tuberculosis rifampin resistance in clinical specimens by using single-tube hemi-nested PCR. J. Clin. Microbiol. 33:556-561.

Moore, S.B., J.R. Kruger, J. Rakela, E.C. Vamvakas, C. Schimek, J.J. Germer, and D.H. Persing. (1995) Blood donors who are repeatedly reactive for hepatitis C virus on enzyme immunoassay and positive on recombinant immunoblot assay: evidence of failure to identify some risk factors. Transfusion 35:308-312.

Weiss, J.B. Jr., and D.H. Persing. (1995) Hepatitis C: advances in diagnosis. Mayo Clin. Proc. 70:296-297.

Laskus, T., J. Rakela, and D.H. Persing. (1995) Nucleotide sequence analysis of precore and proximal core regions in patients with chronic hepatitis B treated with interferon. Dig. Dis. Sci. 40:1-7.

Zein, N.N., J. Rakela, and D.H. Persing. (1995) Genotype-dependent serologic reactivities in patients infected with hepatitis C virus in the United States. Mayo Clin. Proc. 70:449-452.

Gross, J.B. Jr., and D.H. Persing. (1995) Hepatitis C: advances in diagnosis and therapy. Mayo Clin. Proc. 70:296-297.

Felmlee, T.A., Q. Liu, S.S. Sommer, A.C. Whelen, and D.H. Persing. (1995) Genotypic detection of Mycobacterium tuberculosis rifampin resistance: comparison of single strand conformation polymorphism and dideoxy fingerprinting. J. Clin. Microbiol. 33:1617-1623.

Whelen, A.C., T.A. Felmlee, J.M. Hunt, D.L. Williams, G.D. Roberts, L. Stockman, and D.H. Persing. (1995) Direct genotypic detection of Mycobacterium tuberculosis rifampin resistance in clinical specimens by using single-tube heminested PCR. J. Clin. Microbiol. 33:556-561.

Felmlee, T.A., P.S. Mitchell, K.J. Ulfelder, D.H. Persing, and J.P. Landers. (1995) Capillary electrophoresis for the post-amplification detection of a heptitis C virus-specific DNA product in human serum. J. Cap. Elec. 2:125-130.

Zein, N.N., C.G.A. McGregor, N.K. Wendt, K. Schwab, P.S. Mitchell, and D.H. Persing, and J. Rakela. (1995) Hepatitis C infection in heart transplant recipients. J. Heart Lung Transpl. 14:865-869.

Weinstein, J., J.J. Poterucha, D.H. Persing, N.N. Zein, and J. Rakela. (1995) Epidemiology and natural history of hepatitis C infections in liver transplant recipients. J. Hepatol. 22:154-159.

Kolbert, C.P., D.S. Podzorski, A.T. Wortman, A. Gazumyan, I. Schwartz, and D.H. Persing. (1995) Two geographically distinct isolates of Borrelia burgdorferi from the United States share a common unique ancestor. Res. Microbiol.146:415-424.

Pancholi, P., C.P. Kolbert, P.D. Mitchell, K.D. Reed, J.S. Dumler, J.S. Bakken, S.R. Telford III, and D.H. Persing. (1995) Ixodes dammini as a potential vector of human granulocytic ehrlichiosis. J. Infect. Dis. 172:1007-1012.

Pruthi, R.K., W.F. Marshall, J.C. Wiltsie, and D.H. Persing. (1995) Human babesiosis. Mayo Clin. Proc. 70:853-862.

Laskus, T., J. Rakela, M.J. Nowicki, and D.H. Persing. (1995) Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology 109:1618-1623.

Herwaldt, B.L., F.E. Springs, P.P. Roberts, M.L. Eberhard, K. Case, D.H. Persing, and W.A. Agger. (1995) Babesiosis in Wisconsin: a potentially fatal disease. Am. J. Trop. Med. Hyg. 53:146-151.

Podzorski, R.P., and D.H. Persing. (1995) Molecular methods for the detection and identification of infectious agents. J. Histotechnol. 18:225-232.

Kolbert, C.P., J.E. Connolly, M.J. Lee, and D.H. Persing. (1995) Detection of the staphylococcal mecA gene by chemiluminescent DNA hybridization. J. Clin. Microbiol. 33:2179-2182.

Tenover, F.C., R.D. Arbeit, R.V. Goering, P.A. Mickelsen, B.E. Murray, D.H. Persing, and B. Swaminathan. (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.

Fikrig, E., B. Liu, L.L. Fu, S. Das, R.A. Flavell, D.H. Persing, R.T. Schoen, S.W. Barthold, and S.E. Malawista. (1995) An ospA frameshift, identified from DNA in Lyme arthritis synovial fluid, results in an Osp that does not bind protective antibodies. J. Immunol. 155:5700-5704.

Barthold, S.W., E. Fikrig, L.K. Bockenstedt, and D.H. Persing. (1995) Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect. & Immun. 63:2255-2261.

Felmlee, T.A., D.H. Persing, and J.P. Landers. (1995) Capillary electrophoresis of DNA: application to clinical diagnoses. J. Chromatog. 717:127-137.

Zein, N.N., J. Rakela, J.J. Poterucha, and D.H. Persing. (1995) Hepatitis C genotypes in liver transplant patients: distribution and 1-year follow-up. Liver Transplant. Surg. 1:354-357.

Anguita J., D.H. Persing, M. Rincón, S.W. Barthold, and E. Fikrig. (1996) Effect of anti-interleukin 12 treatment on murine Lyme borreliosis. J. Clin. Invest. 97:1028-1034.

Cockerill, F.R., D.E. Williams, K.D. Eisenach, B.C. Kline, L.K. Miller, L. Stockman, J. Voyles, G.M. Caron, S.K. Bundy, G.D. Roberts, W.R. Wilson, A.C. Whelen, J.M. Hunt, and D.H. Persing. (1996) Prospective evaluation of the utility of molecular techniques for diagnosing nosocomial transmission of multidrug-resistant tuberculosis. Mayo Clin. Proc. 71:221-229.

Telenti, A., and D.H. Persing. (1996) Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Res. Microbiol. 147:73-79.

Herwaldt, B.L., D.H. Persing, E.A. Précigout, W.L. Goff, D.A. Mathiesen, P.W. Taylor, M.L. Eberhard, and A.F. Gorenflot. (1996) A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann. Intern. Med. 124:643-650.

Walker, D.H., A. Barbour, J.H. Oliver, R.S. Lane, J.S. Dumler, D.T. Dennis, D.H. Persing, A.F. Azad, and E.S. McSweegan. (1996) Emerging bacterial zoonotic and vector-borne diseases: ecological and epidemiological factors. J. Amer. Med. Assoc. 275:463-469.

Anderson, J.F., R.A. Flavell, L.A. Magnarelli, S.W. Barthold, F.S. Kantor, R. Wallich, D.H. Persing, D. Mathiesen, and E. Fikrig. (1996) Novel Borrelia burgdorferi isolates from Ixodes scapularis and Ixodes dentatus ticks feeding on humans. J. Clin. Microbiol. 34:524-529.

Persing, D.H., and P.A. Conrad. (1996) Babesiosis: new insights from phylogenetic analysis. Infect. Agents & Dis. 4:182-195.

Telford, S.R. III, J.E. Dawson, P. Katavolos, C.K. Warner, C.P. Kolbert, and D.H. Persing. (1996) Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle. Proc. Natl. Acad. Sci. 93:6209-6214.

Krause, P.J., S. Telford III, A. Spielman, V. Sikand, R. Ryan, D. Christianson, G. Burke, P. Brassard, R. Pollack, J. Peck, and D.H. Persing. (1996) Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illness. JAMA 275:1657-1660.

Gewirtz, A.S., P.J. Cornbleet, D.J. Vugia, C. Traver, J. Niederhuber, C.P. Kolbert, and D.H. Persing. (1996) Human granulocytic ehrlichiosis: report of a case in northern California. Clin. Infect. Dis. 23:653-654.
Original Articles, continued:
Zein, N.N., and D.H. Persing. (1996) Hepatitis C genotypes: current trends and future implications. Mayo Clin. Proc. 71:458-462.

Tenover, F.C., B. Swaminathan, R.D. Arbeit, R.V. Goering, P.A. Mickelsen, B.E. Murray, and D.H. Persing. (1996) Diversity among Helicobacter pylori isolates. J. Clin. Microbiol. 34:1041.

MacDonald, K.L., M.T. Osterholm, K.H. LeDell, K.E. White, C.H. Schenck, C.C. Chao, D.H. Persing, R.C. Johnson, J.M. Barker, and P.K. Peterson. (1996) A case-control study to assess the role of silicone-gel breast implants and other factors in chronic fatigue syndrome. Am. J. Med. 100:548-554.

Zein, N.N., J. Rakela, E.L. Krawitt, K.S. Reddy, T. Tominaga, and D.H. Persing. (1996) Hepatitis C genotypes: epidemiology, pathogenicity, and response to interferon therapy. Ann. Intern. Med. 125:634-639.

Nocton, J.J., B.J. Bloom, B.J. Rutledge, and D.H. Persing. (1996) Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. J. Infect. Dis. 174:623-627.

Mathiesen, D., J.H. Oliver Jr., C.P. Kolbert, E. Tullson, B. Johnson, R. Campbell, P. Mitchell, K. Reed, S. Telford III, J. Anderson, R. Lane, and D.H. Persing. (1997) Genetic heterogeneity of Borrelia burgdorferi in the United States. J. Infect. Dis. 175:98-107.

Pancholi, P., R.P. Oda, P.S. Mitchell, J.P. Landers, and D.H. Persing. (1997) Clinical diagnostic detection of hepatitis C and herpes simplex viral PCR amplification products by capillary electrophoresis with laser-induced fluorescence. Mol. Diag. 2:27-38.

Persing D.H. Nucleic acid-based pathogen discovery techniques: application to xenozoonoses. Mol. Diag., in press.

Ramzan, N.N., E. Loftus Jr., L. Burgart, M. Rooney, K. Batts, R.H. Wiesner, D.N. Fredricks, D.A. Relman, and D.H. Persing. Molecular diagnosis and monitoring of Whipple's disease. Ann. Intern. Med., in press.

Zhang, Y.-Q., D. Mathiesen, C.P. Kolbert, J. Anderson, R.T. Schoen, E. Fikrig, and D.H. Persing. B. burgdorferi ELISA for discrimination of OspA vaccination from spirochete infection. J. Clin. Microbiol., in press.

Krause, P.J., R. Ryan, S. Telford III, D.H. Persing, and A. Spielman. Efficacy of an IgM serodiagnostic test for the rapid diagnosis of acute babesiosis. In press.
Krause, P.J., S. Telford III, A. Spielman, R. Ryan, M. Cartter, J. Magera, T.V. Rajan, D. Christianson, T. Maruccha, L. Woody, and D.H. Persing. Comparison of PCR with blood smear and small animal inoculation for diagnosis of Babesia microti parasitemia. In press.

Kolbert, C.P., E.S. Bruinsma, A.S. Abdulkarim, E. Hofmeister, J. Adams-Stich, S.R. Telford III, and D.H. Persing. Direct recovery and characterization of an immunoreactive protein from the agent of human granulocytic ehrlichiosis. J. Clin. Microbiol., in press.

Zein, N.N., J.J. Poterucha, J.B. Gross, Jr., R.H. Wiesner, and D.H. Persing. Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. Gastroenterology, submitted.

Zein, N.N., P.S. Mitchell, and D.H. Persing. Indeterminate second-generation radioimmunoblot assay and the significance of highly reactive C22-3 band. J. Clin. Microbiol., submitted.

Persing, D.H. The cold zone: a curious convergence of tick-transmitted diseases. Clin. Infect. Dis., in press.

Whelen, A.C., and D.H. Persing. The role of nucleic acid amplification and detection in the clinical microbiology laboratory. Microbiol. Rev., submitted.

Alonso, J., D.H. Persing, P. Anda, L.E. Gibson, B.J. Rutledge, and L. Iglesias. No evidence for Borrelia burgdorferi infection in lesions of morphea and lichen sclerosus et atrophicus in Spain: a prospective study and a review of the literature. Submitted.

Gordon, F.D., J.J. Poterucha, J. Germer, N.N. Zein, K.P. Batts, J.B. Gross Jr., R.H. Wiesner, and D.H. Persing. The relationship between hepatitis C genotype and the severity of recurrent hepatitis C after liver transplantation. Submitted.

Zein, N.N., A.J. Czaja, D.H. Persing, P.J. Santrach, S.B. Moore. Viral and genetic factors as determinants of autoimmune expression in chronic hepatitis C. Submitted.

Belongia, E.A., K.D. Reed, P.D. Mitchell, C.P. Kolbert, D.H. Persing, J.S. Gill, J.J. Kazmierczak. Prevalence of granulocytic Ehrlichia infection among white-tailed deer in Wisconsin. In press.

Duffy, J., C.P. Kolbert, B. Rutledge, and D.H. Persing. Active coinfection with B. burgdorferi and the agent of granulocytic ehrlichiosis. The Lancet, in press.

Krause, P.J., S. Telford III, A. Spielman, V.J. Sikand, D. Christianson, P. Brassard, J. Magera, T. Maruccha, M. Cartter, G. Burke, T.V. Rajan, and D.H. Persing. Molecular monitoring of Babesia microti parasitemia: evidence of chronic infections in humans. In preparation.

Hofmeister, E.K., J.E. Childs, and D.H. Persing. Clonal selection for population members may contribute to the maintenance of Borrelia burgdorferi in naturally infected Peromyscus leucopus. In preparation.

Gordon, F.D., N.N. Zein, J.J. Poterucha, R.H. Wiesner, J.B. Gross, and D.H. Persing. Increased risk of histologic recurrence following liver transplantation in patients infected with HCV genotype 1b. Submitted.

Kang, I., S.W. Barthold, D.H. Persing, and L.K. Bockenstedt. T helper cell cytokines in early murine Lyme borreliosis: evidence for coordination of Th1 and Th2 responses in disease resistance. Submitted.

Daoud, M.S., J.B. Gross Jr., R.D. Ellefson, D.H. Persing, and W.P.D. Su. Prevalence of chronic hepatitis C infection in patients with porphyria cutanea tarda in the United States. Submitted.

Guerrero, R.B., K.P. Batts, D.J. Brandhagen, J.J. Germer, R.G. Perez, and D.H. Persing. Effects of formalin fixation and prolonged block storage on detection of hepatitis C virus RNA in liver tissue. Diagn. Mol. Pathol., Submitted.

Guerrero, R.B., K.P. Batts, J.J. Germer, and D.H. Persing. Reverse transcriptase-polymerase chain reaction fails to detect peripheral blood hepatitis C RNA in formalin-fixed liver tissue. Diagn. Mol. Pathol., Submitted.

Hofmeister, E.K., C.P. Kolbert, A.S. Abdulkarim, J.M. Magera, M.K. Hopkins, J.R. Uhl, A. Ambyaye, S.R. Telford III, F.R. Cockerill III, and D.H. Persing. Cosegregation of a novel Bartonella sp. with Borrelia burgdorferi and Babesia microti in Peromyscus leucopus. Submitted.

Czaja, A.J., A.S. Abdulkarim, H.A. Carpenter, R.G. Perez, D.H. Persing, and N.N. Zein. Hepatitis G virus infection in type 1 autoimmune hepatitis. Submitted.

Jahangir, A., C. Kolbert, W. Edwards, P. Mitchell, J.F. Hall, J.S. Dumler, and D.H. Persing. Fatal pancarditis associated with granulocytic ehrlichiosis in a 44-year-old man. N. Engl. J. Med., submitted.

Abstracts:

Persing, D.H., L. McGinty, and R.G. Fowler. (1980) Mutational specificity of the base analogue, 2-amino-purine, in Escherichia coli (Abstract) Genetics, 94, s82.

Persing, D.H., H.E. Varmus, and D. Ganem. (1986) A mutation in the pre-S region of HBV abolishes albumin binding activity of hepatitis B surface antigen polypeptides in Viral Hepatitis, UC San Francisco symposium on viral hepatitis and liver disease.

Persing, D.H., and Edberg, S.C. (1989) Identification and characterization of Chlamydia trachomatis in clinical specimens using the polymerase chain reaction. Annual Meeting, the American Society for Microbiology, New Orleans, LA.

Schillinger, J., P. Rys, and D.H. Persing. (1990) Detection and characterization of HPV infection: comparison of dot-blotting and PCR. Annual Meeting, the American Society for Microbiology, Anaheim, CA.

Shapiro, E., M. Gerber, D. Persing, S. Luger, and H. Feder. (1990) Risk of developing Lyme disease after a deer tick bite in an endemic area. Abstracts, International Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA.

Marshall, W.F, D.J. Dicaudo, P.N. Rys, W.P.D. Su, and D. H. Persing. (1991) The antiquity of Lyme disease: demonstration of Borrelia burgdorferi DNA in archived human tissues. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL.

Mathiesen, D., S.R. Telford, III, A. Spielman, W.F. Marshall, P.A. Conrad and D.H. Persing. (1991) Detection of Babesia microti in parasitemic human blood using the polymerase chain reaction. 5th San Diego Conference on Nucleic Acids, San Diego, CA.

Gustaferro, C., and D.H. Persing. (1991) A chemiluminescent universal probe for bacterial ribotyping. 5th San Diego Conference on Nucleic Acids, San Diego, CA.

Rys, P.N., and D.H. Persing. (1991) Evaluation of photochemical and enzymatic methods for amplicon sterilization. 5th San Diego Conference on Nucleic Acids, San Diego, CA.

Podzorski, D.S., D. Mathiesen, J. Proper, and D.H. Persing. (1991) DNA sequence divergence within the OspA genes of two North American isolates of the Lyme disease spirochete, Borrelia burgdorferi. 5th San Diego Conference on Nucleic Acids, San Diego, CA.

Hopkins, M.K., P.K.W. Yu, D.H. Persing, and J.P. Anhalt. (1991) Simplified scheme for screening of Escherichia coli O157:H7 from Stool Cultures. 91st General Meeting of the American Society for Microbiology, Dallas, Texas.

Gutschenritter, J., P. Schams, C. O'Hara, and D.H. Persing. (1992) Comparison of the Biolog and MIDI systems for identification of Gram-negative nonfermenters. 92nd General Meeting of the American Society for Microbiology, Dallas, Texas.

Piper, K., M.E. Brecher, L. Bland, and D.H. Persing. (1992) Use of a chemiluminescent universal bacterial probe for pre-transfusion screening of blood products. 92nd General Meeting of the American Society for Microbiology, Dallas, Texas.

Uhl, J.R., L. Stockman, N.K. Henry, C.A. Gustaferro, J.E. Rosenblatt, B.C. Kline, and D.H. Persing. (1992) Comparison of pulsed-field gel electrophoresis chemi-luminescent ribotyping and fatty acid analysis for typing Xanthomonas maltophilia. 92nd General Meeting of the American Society for Microbiology, Dallas, Texas.

Thomford, J.W., P.A. Conrad, S.R. Telford III, R. Quick, B. Herwaldt, M. Eberhard, D. Mathieson, and D. Persing. (1992) A new human Babesia in the Western United States. International Conference of Diseases in Nature Communicable to Man, Vancouver, British Columbia.

Douglas, D.D., J. Rakela, H.F. Taswell, D.H. Persing, J. Wilber, R. Sanchez-Pescador, P. Neuwald, and M.S. Urdea. (1992) Correlation of quantitative HCV RNA, anti-HCV IgM, and Serum ALT with histologic presentation. American Association for the Study of Liver Diseases, Chicago, Illinois.

Weinstein, J.S., J. Rakela, D.D. Douglas, D.H. Persing, F.B. Hollinger, H.J. Lin, J.C. Wilber, C.S. Chan, P. Neuwald, and M.S. Urdea. (1992) Comparison of a quantitative HCV-RNA assay to PCR in monitoring the effect of alpha-interferon in patients with chronic hepatitis C. American Association for the Study of Liver Diseases, Chicago, Illinois.

Persing, D.H., W.F. Marshall, S.R. Telford, P.N. Rys, and A. Spielman. (1992) Detection of Borrelia burgdorferi DNA in museum specimens of Peromyscus leucopus. International Conference on Lyme Borreliosis. Arlington, VA.

Krause, P.J., N. Olson, D. Hild, S. Telford, J. Magera, and D.H. Persing. (1993) Identification of Babesia microti in the bone marrow of a renal transplant patient. Infectious Diseases Society of America, Washington, DC.

Tenover, F.C., M.B. Huang, J.K. Rasheed, and D.H. Persing. (1993) Direct detection of ampicillin-resistant Haemophilus influenzae (HI) in cerebrospinal fluid (CSF) by using polymerase chain reaction (PCR). 33rd ICAAC, New Orleans, Louisiana.

Geha, D., and D.H. Persing. (1993) Enzymatic detection of polymerase chain reaction products (ED-PCR) compared to multiplex PCR (MP-PCR) for detection of MecA in Staphylococci. 33rd ICAAC, New Orleans, Louisiana.

Thomford, J.A., P. Conrad, C. Glaser, B. Lane, S. Telford III, D. Mathiesen, B. Bowman, A. Spielman, M. Eberhard, B. Herwaldt, R. Quick, and D.H. Persing. (1993) A newly identified human pathogen is related to the oncogenic parasite Theileria. 33rd ICAAC, New Orleans, Louisiana.

Krause, P., V.J. Sikand, L. Bow, D. Christianson, M. Cartter, J. Magera, and D.H. Persing. (1993) PCR diagnosis of Babesia microti infection in humans. 33rd ICAAC, New Orleans, Louisiana.

Espy, M.J., T.F. Smith, and D.H. Persing. (1993) Effect of amplicon size and nucleotide composition on inactivation by isopsoralen (IP) and uracil-N-glycosylase (UNG) after amplification by polymerase chain reaction (PCR). 93rd ASM General Meeting, Atlanta, Georgia.

Rys, P., and D.H. Persing. (1993) Avoiding false positives with PCR: comparison of three methods for inactivation of amplified DNA. 93rd ASM General Meeting, Atlanta, Georgia.

Hunt, D.J., A. Telenti, G. D. Roberts, L. Stockman, T.A. Felmlee, and D.H. Persing. (1993) Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures and in clinical specimens. 93rd ASM General Meeting, Atlanta, Georgia.

Geha, D., J. Uhl, and D.H. Persing. (1993) Multiplex PCR for identification of methicillin-resistant Staphylococci in the clinical laboratory. 93rd ASM General Meeting, Atlanta, Georgia.
Abstracts, continued:
Persing, D.H., and D. Podzorski. (1993) Genetic transformation of the Lyme disease spirochete. 93rd ASM General Meeting, Atlanta, Georgia.

Kolbert, C., D. Podzorski, D. Mathiesen, and D.H. Persing. (1993) Molecular analysis of strain variation among Borrelia burgdorferi isolates from the United States. 93rd ASM General Meeting, Atlanta, Georgia.

Zein, N.N., J. Rakela, J. Poterucha, R.H. Wiesner, R.A. F. Krom, and D.H. Persing. (1993) HCV genotypes in liver transplant patients. American Gastroenterological Association, New Orleans, Louisiana.

Zein, N. N., J. Rakela, E.L. Krawitt, R. Reddy, V. Idrovo, L. Jeffers, E. Schiff, A.A. Gossard, J.B. Gross, J. Poterucha, and D.H. Persing. (1993) Distribution of HCV genotypes in patients with chronic hepatitis C infection in USA. American Gastroenterological Association, New Orleans, Louisiana.

Laskus, T., J. Rakela, J.W. Mosley, M. Nowicki, and D.H. Persing. (1993) Prevalence and nucleotide sequence analysis of pre-core mutations among patients with fulminant hepatitis in the USA. International Symposium on Viral Hepatitis and Liver Disease, Tokyo, Japan.

Laskus, T., D.H. Persing, J.S. Weinstein, S. Kuwada, R.H. Wiesner, J.L. Steers, and J. Rakela. (1993) Absence of HBV DNA in patients with fulminant NANB hepatitis. AASLD, Chicago, Illinois.

Laskus, T., J. Rakela, J.S. Weinstein, M.J. Tong, and D.H. Persing. (1993) Nucleotide sequence analysis of the precore region in patients with spontaneous reactivation of chronic hepatitis. AASLD, Chicago, Illinois.

Laskus, T., J. Rakela, J.S. Weinstein, M.J. Tong, M. Nowicki, J.W. Mosley, and D.H. Persing. (1993) Core promoter deletions naturally occurring hepatitis B virus (HBV) variants. AASLD, Chicago, Illinois.

Laskus, T., J. Rakela, and D.H. Persing. (1993) The stem-loop structure of the cis-encapsidation signal is highly conserved in naturally occurring hepatitis B virus (HBV) variants. American Gastroenterological Association and AASLD, New Orleans, Louisiana.

Laskus, T., J. Rakela, J.L. Steers, R.H. Wiesner, and D.H. Persing. (1993) Molecular characterization of the precore, core promoter, and proximal core regions of hepatitis B virus (HBV) in patients undergoing orthotopic liver transplantation. American Gastroenterological Association, New Orleans, Louisiana.

Oliver, J., T. Kollars, F. Chandler, E. Masters, R. Lane, D.H. Persing, and P. Duray. (1994) Unusual tick isolates of Borrelia burgdorferi from Southeast Missouri associated geographically and temporally with human Lyme disease. VI International Conference on Lyme Borreliosis, Bologna, Italy.

Whelen, A.C., J. Hunt, T. Felmlee, D. Williams, G. Roberts, L. Stockman, and D.H. Persing. (1994) Rapid and specific PCR-based detection of drug-resistant and sensitive Mycobacterium tuberculosis American Society for Microbiology, Las Vegas, Nevada.

Schutzer, S.E., and D.H. Persing. (1994) Surrogate markers of active infection in vaccine trials. CSH Vaccine Meeting, Banbury Conference on Vaccine Development, Cold Spring Harbor, New York.
Abstracts, continued:
Zein, N.N., C.G.A. McGregor, K. Schwab, N.K. Wendt, P.S. Mitchell, D.H. Persing, and J. Rakela. (1994) Prevalence of hepatitis C infection among heart transplant recipients. American Association for the Study of Liver Diseases, Chicago, Illinois.

Zein, N.N., J. Rakela, E.L. Krawitt, J. Poterucha, J.B. Gross, Jr., A.A. Gossard, and D.H. Persing. (1994) Response to interferon in patients with different HCG genotypes in U.S.A. American Association for the Study of Liver Diseases, Chicago, Illinois.

Nocton, J.J., B. Bloom, B.J. Rutledge, P.N. Rys, D.H. Persing, and A.C. Steere. (1994) Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in patients with neurologic involvement in Lyme disease. 58th Annual Scientific Meeting of the American College of Rheumatology, Minneapolis, Minnesota.

Zein, N.N., C.G.A. McGregor, K. Schwab, P.S. Mitchell, N.K. Wendt, D.H. Persing, and J. Rakela. (1995) Prevalence and outcome of hepatitis C infection among heart transplant recipients. International Society for Heart and Lung Transplantation, San Francisco, California.

Felmlee, T.A., D.H. Persing, and J.P. Landers. (1995) Capillary electrophoretic determination of single point mutations in DNA: potential clinical applications.

Dumler, J.S., J.S. Bakken, P.D. Mitchell, C.P. Kolbert, P. Pancholi, and D.H. Persing. (1995) Human granulocytic ehrlichiosis (HGE), Lyme disease, and babesiosis in the Upper Midwest: evidence for concurrent infections. 35th ICAAC, San Francisco, CA.

Kolbert, C.P., P. Pancholi, P. Mitchell, K. Reed, J.S. Dumler, J. Bakken, and D.H. Persing. (1995) Evidence for human granulocytic ehrlichiosis in patients with suspected Lyme disease. American Society for Microbiology, Washington, DC.

Krause, P., S. Telford III, A. Spielman, V.J. Sikand, R. Ryan, D. Christianson, P. Brassard, R. Pollack, G. Burke, and D.H. Persing. (1995) Increased severity of Lyme disease illness due to concurrent babesiosis. 35th ICAAC, San Francisco, CA.

Gross, J., N. Zein, J. Germer, J. Poterucha, A. Gossard, N. Wendt, P. Mitchell, N. Ramzan, and D.H. Persing. (1995) Changes in predominant hepatitis C genotype during alpha-interferon therapy. EASL Meeting.

Zein, N., J. Gross, A. Gossard, R. Wiesner, J. Poterucha, and D.H. Persing. (1995) Significance of hepatitis C virus (HCV) RNA levels in orthotopic liver transplant recipients (OLT). EASL Meeting.

Schimek, C.M., N.N. Zein, N.K. Wendt, P.S. Mitchell, J.J. Germer, J.N. Thorvilson, and D.H. Persing. (1995) Correlation between strong RIBA 2.0 c22-3 indeterminate results and HCV viremia in HCV EIA reactive subjects. American Association of Blood Banks, 48th Annual Meeting, New Orleans, LA.

Zein, N., J. Gross, A. Gossard, R. Wiesner, J. Poterucha, and D.H. Persing. (1995) Significance of hepatitis C virus (HCV) RNA levels in orthotopic liver transplant (OLT) recipients. Joint Congress on Liver Transplantation, London, England.

Smith, C.I., K.D. Lake, J.A. Haroldson, D.H. Persing, R.W. Emery, and M.R. Pritzker. (1995) Clinical experience with hepatitis C (HCV) infection in a cardiac transplant center. American Association for the Study of Liver Diseases, Chicago, IL.

Krause, P.J., S.R. Telford III, A. Spielman, V.J. Sikand, R. Ryan, D. Christianson, P. Brassard, R. Pollack, G. Burke, and D.H. Persing. (1995) 535 increased severity of Lyme disease illness due to concurrent babesiosis. American Society of Tropical Medicine and Hygiene.

Gupta, P., R.W. Hurley, D.H. Persing, and D.E. Hammerschmidt. (1995) Acute relapsing Babesia microti infection in an immunocompromised host: important lessons for the hematologist. American Society of Hematology, Seattle, WA.

Persing, D.H. (1995) Molecular diagnostic methods and infectious diseases: today and tomorrow. 33rd Annual IDSA Meeting, San Francisco, CA.

Oda, R.P., J.J. Germer, D.H. Persing, and J.P. Landers. (1996) Capillary electrophoresis in polymer networks with laser-induced fluorescence detection as a rapid diagnostic test for tick-transmitted diseases. 8th International Symposium on High Performance Capillary Electrophoresis, Orlando, FL.

Zein, N.N., D.H. Persing, and A.J. Czaja. (1996) Viral and genetic factors as determinants of autoimmune expression in chronic hepatitis C. American Gastroenterological Association and American Association for the Study of Liver Diseases, Chicago, IL.

Brandhagen, D.J., J.J. Poterucha, J.B. Gross Jr., W.R. Kim, R.G. Perez, J.J. Germer, A.A. Gossard, J. Detmer, J. Kolberg, M. Collins, and D.H. Persing. (1996) Hepatitis G infection in patients undergoing inferferon treatment for chronic hepatitis C: clinical characteristics and HGV RNA levels. American Association for the Study of Liver Diseases, Chicago, IL.

Brandhagen, D.J., J.B. Gross Jr., K.P. Batts, F.D. Gordon, R.H. Wiesner, A.A. Gossard, D.H. Persing, and J.J. Poterucha. (1996) Recurrence of hepatitis C after transplant: significance of HLA match and HCV genotype. American Association for the Study of Liver Diseases, Chicago, IL.

Brandhagen, D.J., J.B. Gross Jr., J.J. Poterucha, W.R. Kim, M.R. Charlton, R.G. Perez, J.J. Germer, J. Detmer, J. Kolberg, M. Collins, R.H. Wiesner, and D.H. Persing. (1996) Hepatitis G infection as determined by bDNA in patients with hepatitis C undergoing liver transplantation: clinical characteristics and viral levels. American Association for the Study of Liver Diseases, Chicago, IL.

Abdulkarim, A.S., N.N. Zein, L. Kabbani, A. Hawla, N. Agha, M. Tourogman, K.L. Krajnik, J.J. Germer, C.P. Kolbert, and D.H. Persing. (1996) Hepatitis C (HCV) genotype and hepatitis G (HGV) in hemodialysis patients from Syria: the identification of two novel hepatitis C subtypes. American Association for the Study of Liver Diseases, Chicago, IL.

Zein, N.N., A.S. Abdulkarim, D. Brandhagen, T. Therneau, and D.H. Persing. (1996) Chronic hepatitis C infection (HCV) in the U.S.: an insight into the natural history and evidence for a change in the epidemiology of HCV genotypes. American Association for the Study of Liver Diseases, Chicago, IL.

Zein, N.N., A.S. Abdulkarim, R.H. Wiesner, and D.H. Persing. (1996) Increased risk for diabetes mellitus type II (DM) with chronic hepatitis C infection (HCV). American Association for the Study of Liver Diseases, Chicago, IL.

Charlton, M.R., D. Brandhagen, J.J. Poterucha, J.B. Gross Jr., J. Detmer, M. Collins, J. Kolberg, R.A.F. Krom, R.H. Wiesner, and D.H. Persing. (1996) Prevalence, titers and histology of HGV infection pre- and one year post-OLT in patients transplanted for cryptogenic cirrhosis. American Association for the Study of Liver Diseases, Chicago, IL.

Lake, K.D., C.I. Smith, J. Germer, D.H. Persing, M.R. Pritzker, and R.W. Emery. (1996) Hepatitis C (HCV) genotyping of cardiac transplant recipients. American Association for the Study of Liver Diseases, Chicago, IL.

Czaja, A.J., A.S. Abdulkarim, D.H. Persing, and N.N. Zein. (1997) Hepatitis G virus in type 1 autoimmune hepatitis. American Gastroenterological Association and American Association for the Study of Liver Diseases.

EXHIBIT 3:

SELECTED PAGES FROM

Diagnostic Molecular Microbiology

PRINCIPLES AND APPLICATIONS

EDITED BY PERSING, ET AL.

(Pages 126-127)

EXHIBIT 3:

SELECTED PAGES FROM

Diagnostic Molecular Microbiology

PRINCIPLES AND APPLICATIONS

EDITED BY PERSING, ET AL.

(Pages 126-127)